26 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
16 Jun 22
Regulation FD Disclosure
7:08am
modulators have a beneficial impact α - synuclein oligomer - induced trafficking deficits (red) are reversed by Cognition drug (black) Cognition antagonists … oligomers in red Cognition compounds (black and gray) reverse the effect of α - synuclein oligomers on LAMP2a (orange) Limegrover CS, et al. J Neurosci Res
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
deficits (red) are reversed by Cognition drug (black) Cognition antagonists block the binding / internalization of α-synuclein oligomers at synapses … ;-synuclein oligomers ;-synuclein oligomers + CT1812 ;-Synuclein oligomers in red Cognition compounds (black and gray) reverse the effect of α-synuclein
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
10 Jan 22
Regulation FD Disclosure
7:01am
- synO + drug Vehicle alone (no deficit) α - synuclein oligomer - induced trafficking deficits (red) are reversed by Cognition drug (black) Cognition … - Synuclein oligomers in red Cognition compounds (black and gray) reverse the effect of α - synuclein oligomers on LAMP2a (orange) Limegrover CS, et al. Sigma
10-Q
npegqsgm0d04rh5b5xc
17 Nov 21
Quarterly report
5:15pm
DEF 14A
bxul5
25 Apr 22
Definitive proxy
5:28pm
10-K
a2ifk0 96fs8cu
30 Mar 22
Annual report
7:40am
424B4
hx9x5j0tgbl3qx
12 Oct 21
Prospectus supplement with pricing info
4:11pm
DRS
7g361n4ur 5dbp6p4t
7 May 21
Draft registration statement
12:00am